Tampa, Florida, United States – TheNewswire – April 18, 2022 – CTT Pharmaceutical Holdings, Inc. (OTC:CTTH) is announcing today that we have recently filed a patent application encompassing nicotine-containing orally administrable strips. The continuation-in-part application stems from our previously granted US Patent for similar orally administrable strips and is, thus, based on technology already determined to be patentable by the United States Patent and Trademark Office. The strips have been developed to deliver an agent such as nicotine for absorption by the oral mucosa. This patent covers dissolvable strips containing nicotine from various sources, including organically-derived nicotine, as well as synthetic and non-synthetic nicotine. Strengthening our Nicotine Patent portfolio was a priority of mine as the new CEO, as I believe our smoke-free technology offers CTT an opportunity in the US tobacco market. A market that is currently undergoing changes with the Biden Administration’s proposed ban on menthol cigarettes and cigars which is expected to take place April 2022. I commend the Administration for taking this initial step as smoking kills more than 480,000 Americans every year or 1300 Americans daily, per the CDC. Making cigarette smoking a pandemic in its own right. Furthermore, with current oral nicotine products such as dip, lozenges, and chewing gum I believe there is room for more smoke-free products, especially for quick dissolving options. Our dissolvable strips would give nicotine users an oral smoke-free product to choose from that is currently not available to customers in the United States.
CTT Pharma’s nicotine strips dissolve in your mouth in seconds, then enters the bloodstream, bypassing the lungs and digestive tract including your liver. This allows for fast onset, better absorption/bioavailability, and the ability to add/combine actives to our Nicotine strips, such as CBD, B12, Caffeine, Etc. I’m looking for CTT Pharma and a tobacco or non–tobacco company to monetize our existing nicotine patents and the patents that are pending in the US. Simultaneously CTT will look to get funding from the Biden Administration for FDA Approval and/or help with the development of our Nicotine Strips. CTT Pharma will continue to update our shareholders as more news becomes available.
Thank you for taking some time to read this letter.
Ryan Khouri
CEO of CTT Pharma
813-606-0060
www.linkedin.com/in/ryan-khouri-679a251b7
www.cttpharmaceuticals.com
Copyright (c) 2022 TheNewswire – All rights reserved.
